Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nutlin-3a selects for cells harbouring TP53 mutations.

International journal of cancer - 15 Feb 2017

Kucab Jill E, Hollstein Monica, Arlt Volker M, Phillips David H

Abstract excerpt

TP53 mutations occur in half of all human tumours. Mutagen-induced or spontaneous TP53 mutagenesis can be studied in vitro using the human TP53 knock-in (Hupki) mouse embryo fibroblast (HUF) immortalisation assay (HIMA). TP53 mutations arise in up to 30% of mutagen-treated, immortalised HUFs; however, mutants are not identified until TP53 sequence analysis following immortalisation (2-5 months) and much effort is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Transformed
Share to Clone Cells
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knock-In Techniques

Share to Imidazoles

Share to Oxygen

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Source

Open in PubMed Open full text

Identifiers

PMID: 27813088
DOI: 10.1002/ijc.30504
PMCID: PMC5215675

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nutlin-3a selects for cells harbouring TP53 mutations.PMID 27813088Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma CellsSemantic proximity Read ↗

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Semantic proximity Read ↗

TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts.Semantic proximity Read ↗

In vitro selection of mutant HDM2 resistant to Nutlin inhibition.Semantic proximity Read ↗

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.Semantic proximity Read ↗

Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequencesSemantic proximity Read ↗

Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53 -Deficient CancersSemantic proximity Read ↗

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3Semantic proximity Read ↗

Immortalization of mutant p53-transfected human fibroblasts by treatment with either 4-nitroquinoline 1-oxide or X-rays.Semantic proximity Read ↗

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxiaSemantic proximity Read ↗

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.